Literature DB >> 15247196

Acetazolamide prevents hypoxic pulmonary vasoconstriction in conscious dogs.

Claudia Höhne1, Martin O Krebs, Manuela Seiferheld, Willehad Boemke, Gabriele Kaczmarczyk, Erik R Swenson.   

Abstract

Acute hypoxia increases pulmonary arterial pressure and vascular resistance. Previous studies in isolated smooth muscle and perfused lungs have shown that carbonic anhydrase (CA) inhibition reduces the speed and magnitude of hypoxic pulmonary vasoconstriction (HPV). We studied whether CA inhibition by acetazolamide (Acz) is able to prevent HPV in the unanesthetized animal. Ten chronically tracheotomized, conscious dogs were investigated in three protocols. In all protocols, the dogs breathed 21% O(2) for the first hour and then 8 or 10% O(2) for the next 4 h spontaneously via a ventilator circuit. The protocols were as follows: protocol 1: controls given no Acz, inspired O(2) fraction (Fi(O(2))) = 0.10; protocol 2: Acz infused intravenously (250-mg bolus, followed by 167 microg.kg(-1).min(-1) continuously), Fi(O(2)) = 0.10; protocol 3: Acz given as above, but with Fi(O(2)) reduced to 0.08 to match the arterial Po(2) (Pa(O(2))) observed during hypoxia in controls. Pa(O(2)) was 37 Torr during hypoxia in controls, mean pulmonary arterial pressure increased from 17 +/- 1 to 23 +/- 1 mmHg, and pulmonary vascular resistance increased from 464 +/- 26 to 679 +/- 40 dyn.s(-1).cm(-5) (P < 0.05). In both Acz groups, mean pulmonary arterial pressure was 15 +/- 1 mmHg, and pulmonary vascular resistance ranged between 420 and 440 dyn.s(-1).cm(-5). These values did not change during hypoxia. In dogs given Acz at 10% O(2), the arterial Pa(O(2)) was 50 Torr owing to hyperventilation, whereas in those breathing 8% O(2) the Pa(O(2)) was 37 Torr, equivalent to controls. In conclusion, Acz prevents HPV in conscious spontaneously breathing dogs. The effect is not due to Acz-induced hyperventilation and higher alveolar Po(2), nor to changes in plasma endothelin-1, angiotensin-II, or potassium, and HPV suppression occurs despite the systemic acidosis with CA inhibition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247196     DOI: 10.1152/japplphysiol.01217.2003

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  10 in total

1.  Antioxidants reverse depression of the hypoxic ventilatory response by acetazolamide in man.

Authors:  Luc J Teppema; Hans Bijl; Raymonda R Romberg; Albert Dahan
Journal:  J Physiol       Date:  2006-05-01       Impact factor: 5.182

2.  Lung disease at high altitude.

Authors:  Joshua O Stream; Andrew M Luks; Colin K Grissom
Journal:  Expert Rev Respir Med       Date:  2009-12       Impact factor: 3.772

3.  Acute high-altitude illness: a clinically orientated review.

Authors:  Tom Smedley; Michael Pw Grocott
Journal:  Br J Pain       Date:  2013-05

Review 4.  New insights into carbonic anhydrase inhibition, vasodilation, and treatment of hypertensive-related diseases.

Authors:  Erik R Swenson
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

5.  Effect of acetazolamide on pulmonary and muscle gas exchange during normoxic and hypoxic exercise.

Authors:  Amy M Jonk; Irene P van den Berg; I Mark Olfert; D Walter Wray; Tatsuya Arai; Susan R Hopkins; Peter D Wagner
Journal:  J Physiol       Date:  2007-01-11       Impact factor: 5.182

6.  Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent.

Authors:  Tao Ke; Jiye Wang; Erik R Swenson; Xiangnan Zhang; Yunlong Hu; Yaoming Chen; Mingchao Liu; Wenbin Zhang; Feng Zhao; Xuefeng Shen; Qun Yang; Jingyuan Chen; Wenjing Luo
Journal:  High Alt Med Biol       Date:  2013-06       Impact factor: 1.981

7.  Pulmonary vasodilation by acetazolamide during hypoxia: impact of methyl-group substitutions and administration route in conscious, spontaneously breathing dogs.

Authors:  Philipp A Pickerodt; Roland C Francis; Claudia Höhne; Friederike Neubert; Stella Telalbasic; Willehad Boemke; Erik R Swenson
Journal:  J Appl Physiol (1985)       Date:  2014-01-30

8.  Proteomics discovery of pulmonary hypertension biomarkers: Insulin-like growth factor binding proteins are associated with disease severity.

Authors:  Melanie K Nies; Jun Yang; Megan Griffiths; Rachel Damico; Jie Zhu; Dhananjay Vaydia; Zongming Fu; Stephanie Brandal; Eric D Austin; Dunbar D Ivy; Paul M Hassoun; Jennifer E Van Eyk; Allen D Everett
Journal:  Pulm Circ       Date:  2022-04-20       Impact factor: 2.886

9.  The noncarbonic anhydrase inhibiting acetazolamide analog N-methylacetazolamide reduces the hypercapnic, but not hypoxic, ventilatory response.

Authors:  Luc J Teppema; Erik R Swenson
Journal:  Physiol Rep       Date:  2015-08

Review 10.  Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders.

Authors:  Akylbek Sydykov; Argen Mamazhakypov; Abdirashit Maripov; Djuro Kosanovic; Norbert Weissmann; Hossein Ardeschir Ghofrani; Akpay Sh Sarybaev; Ralph Theo Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-02-10       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.